Literature DB >> 3639011

Effects of kallidinogenase on urinary kallikrein excretion and plasma prostanoid concentrations in patients with essential hypertension.

K Ogawa, T Ito, M Ban, M Motizuki, T Satake.   

Abstract

The effects of kallidinogenase on urinary kallikrein excretion, plasma immunoreactive prostanoids and platelet aggregation were investigated in patients with essential hypertension. Urinary kallikrein excretion and plasma 6-keto PGF1 alpha concentration were significantly decreased in these patients. Significant decreases in blood pressure, as well as significant increases of urinary kallikrein excretion and plasma 6-keto PGF1 alpha concentration after kallidinogenase administration were also observed.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3639011     DOI： 10.1007/BF01940711

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  11 in total

Review 1.  Relationships between the kallikrein-kinin and prostaglandin systems.

Authors:  A Nasjletti; K U Malik
Journal:  Life Sci       Date:  1979-07-09       Impact factor: 5.037

2.  The role of renal prostaglandin E and kallikrein in pathogenesis of essential hypertension.

Authors:  K Abe; M Yasujima; Y Sakurai; S Chiba; T Itoh; Y Imai; M Sato; T Haruyama; K Omata; T Goto; K Sato; M Hiwatari; Y Otsuka; K Yoshinaga
Journal:  Jpn Circ J       Date:  1979-12

3.  Altered urinary kallikrein excretion in human hypertension.

Authors:  H S Margolis; R Geller; J J Pisano; A Sjoerdsma
Journal:  Lancet       Date:  1971-11-13       Impact factor: 79.321

4.  Production of prostacyclin-like substance in stroke-prone and stroke-resistant spontaneously hypertensive rats.

Authors:  M Okuma; Y Yamori; K Ohta; H Uchino
Journal:  Prostaglandins       Date:  1979-01

5.  Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease.

Authors:  H S Margolius; D Horwitz; J J Pisano; H R Keiser
Journal:  Fed Proc       Date:  1976-02

6.  The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements.

Authors:  K Shimamoto; J Chao; H S Margolius
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

7.  Increased plasma concentrations of prostacyclin metabolite 6-keto-PGF1 alpha in essential hypertension. Influence of therapy with labetalol.

Authors:  L Roy; J Mehta; P Mehta
Journal:  Am J Cardiol       Date:  1983-02       Impact factor: 2.778

Review 8.  The renal kallikrein-kinin system in human and in experimental hypertension.

Authors:  O A Carretero; A G Scicli
Journal:  Klin Wochenschr       Date:  1978

9.  Plasma levels of 6-keto-prostaglandin F1 alpha in normotensive subjects and patients with essential hypertension.

Authors:  Y Uehara; M Ishii; T Ikeda; K Atarashi; T Takeda; S Murao
Journal:  Prostaglandins Leukot Med       Date:  1983-05

10.  Changes of plasma 6-keto-PGF1 alpha and thromboxane B2 levels and platelet aggregation after tourniquet ischemia on the upper limb in normal subjects and patients with ischemic heart disease.

Authors:  L S Chen; T Ito; K Ogawa; T Satake
Journal:  Jpn Circ J       Date:  1982-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.